TABLE 2

Demographic and clinical characteristics of patients included in the patient follow-up cohort

Patient characteristicNo low-frequency
DRMs (n = 47)
Low-frequency DRMs
detected (n = 22)
P valueaAll patients
(n = 69)
Patient age, yr median (IQR)40 (32–48)40 (36–51)0.3440 (33-48)
Men, n (%)43 (91)18 (82)0.4461 (88)
Total follow-up in days, median (IQR)656 (557–705)713 (638–750)0.46674 (560–728)
Plasma HIV RNA baseline, in log10 copies/ml, median (IQR); missing4.2 (3.6–4.9); 44.2 (3.9–4.6); 10.414.2 (3.8–4.8); 5
Virological failure, n (%); rate (per 10,000 person-days)16 (34); 6.411 (50); 10.30.3227 (39); 7.5
Changed drug regimen from baseline, n (%)10 (21)2 (9)0.3712 (17)
Received repeat Sanger resistance genotyping in follow-up, n (%)9 (19)3 (14)0.8212 (17)
Treatment naïve, n (%)14 (30)4 (18)0.4718 (26)
Drugs included in prescribed regimen, no. (%) of patients
 PI15 (32)6 (27)0.9121 (30)
 NRTI47 (100)22 (100)69 (100)
 NNRTI3 (6)0 (0)0.203 (4)
 INSTI39 (83)17 (77)0.8156 (81)
Reported as resistant to any drug by clinical genotyping, n (% of tests)16 (34)9 (41)0.7825 (36)
Low-frequency DRM detected, n (%)22 (32)
 PI06 (27)6
 NRTI09 (41)9
 NNRTI07 (32)7
 INSTI04 (18)4
  • a Student's t test (means) or proportion test was used, as applicable, to compare patients with no low-frequency DRMs to those with low-frequency DRMs.